In this study, we confirmed the role of LLS30 as a Gal-1 inhibitor for treating MPNST, demonstrating that LLS30 disrupts the Gal-1/Ras interaction, leading to Ras dissociation from the plasma membrane and subsequent suppression of Ras activation. Here, LGALS1 is linked to malignant peripheral nerve sheath tumor.